跳至主要内容
临床试验/NCT05107193
NCT05107193No Longer Available不适用

Assessment of Prospective Real-world Outcomes Based on Single-patient Protocol Data Collection of Afatinib (GILOTRIF®) Use in Patients With Solid Tumors Harboring NRG1 Gene Fusions

Boehringer Ingelheim0 个研究点开始时间: 2021年11月4日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
No Longer Available

研究概览

简要总结

Gene fusions are defined as two separate genes joined together (gene 1, gene 2), generating a novel fusion gene. NRG1 fusions are rare and complex with regard to the fusion/fusion partner. The specific NRG1 gene fusion will be identified by a specialized molecular testing lab.

详细描述

Afatinib is provided on a single-patient protocol basis to patients suffering from tumors harboring NRG1 fusions, a disease for which no satisfactory authorised alternative therapy exists.

In the context of this mechanism it is planned to collect and analyze limited clinical data in order to investigate the safety and efficacy of afatinib in patients with advanced and/or metastatic solid tumours harboring NRG1 gene fusions.

研究设计

研究类型
Expanded Access

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • Treatment with a systemic anti-cancer therapy or investigational drug within 14 days or 5 half-lives (whichever is shorter) of the first treatment with the study medication.
  • Tumors carrying additional gene mutations other than NRG1 fusion where FDA-approved targeted therapy is available
  • Prior treatment with a therapy targeting erythroblastic leukemia viral oncogene homologue receptors (ErbB)
  • Any patient considered ineligible by the treating physician.

研究者

申办方类型
Industry
责任方
Sponsor

相似试验

Afatinib (GILOTRIF®) in Patients Suffering From... | 临床试验